Effect of neuraminidase treatment on serum reactivity to autologous leukemic blast cells.
The sera of 35 patients with acute lymphoblastic leukemia (ALL) and acute non-lymphoblastic leukemia (ANLL) were tested for reactivity against cell surface antigens of autologous leukemic blast cells by protein A assay (PA), immune adherence assay (IA), and anti-C3 mixed hemadsorption assay (C3-MHA). Autologous serum reactivity was detectable by PA in four cases and by IA and C3-MHA in about half the patients. Autologous serum reactivity occurred more often in ALL than in ANLL. Absorption studies revealed that in one patient only the autologous reactivity was directed against a restricted antigen, which could be detected only on the individual T-ALL blast cells. All other autologous antibodies detected unspecific antigens. Neuraminidase treatment had two effects: first, it increased antibody attachment to antigens which are also present on untreated cells; secondly, after neuraminidase treatment an antigen was detectable on the cell surface which could also be demonstrated on neuraminidase-treated non-leukemic cells (e.g., erythrocytes). Neither of these two effects of neuraminidase treatment seems to be tumor-specific. Possible therapeutic effects of neuraminidase are probably caused by unspecific adjuvant effects of the enzyme.
D000293:Adolescent; D000328:Adult; D000912:Antibodies, Neoplasm / Q000032:analysis*; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D000939:Epitopes; D005260:Female; D006801:Humans; D007223:Infant; D007945:Leukemia, Lymphoid / Q000276:immunology*; D015470:Leukemia, Myeloid, Acute / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009439:Neuraminidase / Q000276:immunology*; D012794:Sialic Acids / Q000276:immunology*
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D000939:Epitopes; D012794:Sialic Acids; D009439:Neuraminidase